Stock 1672 ASCLETIS PHARMA INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Ascletis Pharma Inc.

Equities

1672

KYG0520K1094

Delayed Hong Kong S.E.
Other stock markets
 04:08:15 2024-04-18 am EDT 		5-day change 1st Jan Change
1.27 HKD -2.31% Intraday chart for Ascletis Pharma Inc. -5.93% -13.01%
Apr. 03 Ascletis Discontinues Trials of FXR Agonist for Biliary Cholangitis, NASH and Hepatitis B Virus MT
Apr. 03 Ascletis Pharma Inc. Announces Strategic Decisions on FXR Agonist ASC42 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Ascletis Discontinues Trials of FXR Agonist for Biliary Cholangitis, NASH and Hepatitis B Virus
MT
Ascletis Announces Strategic Decisions on FXR agonist ASC42
PR
Ascletis Pharma Inc. Announces Strategic Decisions on FXR Agonist ASC42
CI
Ascletis Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Ascletis Pharma Inc. Announces Poster Presentation of Phase II Study Final Results of FASN Inhibitor ASC40 for Treatment of Acne at 2024 AAD Annual Meeting
CI
Ascletis Pharma Doses First Patient in Phase 3 Clinical Trial of Acne Vulgaris Drug
MT
Ascletis Announces Dosing of the First Patient in Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acne
PR
Ascletis Pharma Inc. Announces Dosing of the First Patient in Phase III Clinical Trial of Asc40 (Denifanstat) for Treatment of Acne
CI
Gannex's Strategic Partner Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH
PR
Ascletis Pharma's Liver Treatment Reduces Fat in 9 of 10 Participants During Phase 2 Trial
MT
Gannex Announces Positive Interim Results from 52-Week Phase II Clinical Trial of Once-Daily ASC41 Tablet in Patients with Biopsy-Confirmed Non-alcoholic Steatohepatitis
PR
Ascletis Pharma Inc. Announces Positive Interim Results from 52-Week Phase Ii Clinical Trial of Once-Daily Asc41 Tablet in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis
CI
Ascletis Announces Initiation of Phase III Clinical Trial of ASC40 for Treatment of Acne
AQ
Ascletis Pharma Gets Nod to Trial Acne Drug
MT
Ascletis Announces Initiation of Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acne
PR
Ascletis Pharma Inc. Announces Initiation of Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acne
CI
Ascletis Pharma Presents Data on Studies for Liver Treatments at US Liver Disease Meet
MT
Ascletis Pharma Publishes Results of Gannex's Fatty Liver Medication
MT
Ascletis Pharma Presents Data in Germany from Phase 2 Study on Anti-Acne Drug
MT
Ascletis Announces Poster Presentation of Phase II Study Topline Results of FASN Inhibitor ASC40 for Treatment of Acne at EADV Congress 2023
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 1672 Stock
  4. News Ascletis Pharma Inc.